Arecor Therapeutics PLC (AREC) - Total Liabilities
Based on the latest financial reports, Arecor Therapeutics PLC (AREC) has total liabilities worth GBX1.65 Million GBX (≈ $200.39 USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Arecor Therapeutics PLC - Total Liabilities Trend (2017–2025)
This chart illustrates how Arecor Therapeutics PLC's total liabilities have evolved over time, based on quarterly financial data. See AREC current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Arecor Therapeutics PLC Competitors by Total Liabilities
The table below lists competitors of Arecor Therapeutics PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Multistack International Ltd
AU:MSI
|
Australia | AU$2.90 Million |
|
Checkit PLC
LSE:CKT
|
UK | GBX8.70 Million |
|
Global PVQ SE
HM:QCE
|
Germany | €1.18 Billion |
|
Sino-German United AG
F:SGU
|
Germany | €1.03 Million |
|
Elixxer Ltd
V:ELXR
|
Canada | CA$17.22 Million |
|
Altair Resources Inc
V:AVX
|
Canada | CA$3.11 Million |
|
Shuttle Pharmaceuticals Inc
NASDAQ:SHPH
|
USA | $8.46 Million |
|
Annum Bhd
KLSE:5082
|
Malaysia | RM20.48 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Arecor Therapeutics PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Arecor Therapeutics PLC worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arecor Therapeutics PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arecor Therapeutics PLC (2017–2025)
The table below shows the annual total liabilities of Arecor Therapeutics PLC from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | GBX1.65 Million ≈ $200.39 |
-51.17% |
| 2024-12-31 | GBX3.37 Million ≈ $410.40 |
-42.34% |
| 2023-12-31 | GBX5.85 Million ≈ $711.78 |
+35.73% |
| 2022-12-31 | GBX4.31 Million ≈ $524.40 |
+81.70% |
| 2021-12-31 | GBX2.37 Million ≈ $288.60 |
-32.42% |
| 2020-12-31 | GBX3.51 Million ≈ $427.07 |
+219.76% |
| 2019-12-31 | GBX1.10 Million ≈ $133.56 |
-11.12% |
| 2019-05-31 | GBX1.23 Million ≈ $150.26 |
-11.56% |
| 2018-05-31 | GBX1.40 Million ≈ $169.90 |
+13.33% |
| 2017-05-31 | GBX1.23 Million ≈ $149.92 |
-- |
About Arecor Therapeutics PLC
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a no… Read more